GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.

@article{Lee2006GTI2501AA,
  title={GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.},
  author={Y. Lee and A. Vassilakos and Ningping Feng and Hongnan Jin and M. Wang and K. Xiong and Jim A. Wright and A. Young},
  journal={International journal of oncology},
  year={2006},
  volume={28 2},
  pages={
          469-78
        }
}
GTI-2501 is a 20-mer oligonucleotide that is complementary to a coding region in the mRNA of R1, the large subunit of ribonucleotide reductase (RNR). In vitro studies, have demonstrated that GTI-2501 decreases mRNA and protein levels of R1 in a sequence-specific and dose-dependent manner. Furthermore, GTI-2501 inhibits the growth of human lung, liver, ovary, brain, melanoma, breast and pancreatic tumor cells in colony forming assays. In vivo studies have shown that GTI-2501 significantly… Expand
Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors.
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase
Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents.
Targeting ribonucleotide reductase for cancer therapy
...
1
2
3
...

References

SHOWING 1-10 OF 31 REFERENCES
Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential.
  • H. Fan, C. Villegas, J. Wright
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1996
Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs.
Antisense oligonucleotides as therapeutics for malignant diseases.
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
...
1
2
3
4
...